Quick Answer
Vivos Therapeutics, Inc. reported Total Revenue of $15.03 million for fiscal year 2024.
Vivos Therapeutics, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $15.03M +8.9% |
$13.80M -13.9% |
$16.02M -5.1% |
$16.89M +29.2% |
$13.07M +14.7% |
$11.39M |
| Revenue (ASC 606) | $15.03M +8.9% |
$13.80M -13.9% |
$16.02M -5.1% |
$16.89M +29.2% |
$13.07M +14.7% |
$11.39M |
| Net Income | -$11.14M +18.0% |
-$13.58M +43.0% |
-$23.84M -17.5% |
-$20.29M -68.3% |
-$12.06M -12.1% |
-$10.75M |
| Diluted EPS | -$2.22 +80.1% |
-$11.14 +57.0% |
-$25.90 | — | — | — |
| Total Assets | $15.28M +42.4% |
$10.73M -21.8% |
$13.72M -59.3% |
$33.69M +33.0% |
$25.33M +235.4% |
$7.55M |
| Cash and Equivalents | $6.26M +281.0% |
$1.64M -53.3% |
$3.52M -85.4% |
$24.03M +32.0% |
$18.21M +3779.0% |
$469.4K |
| Long-Term Debt | — | — | — | — | $423.0K | — |
| Stockholders Equity | $7.95M +1835.3% |
$411.0K -91.4% |
$4.80M -81.2% |
$25.54M +51.0% |
$16.92M +674.8% |
-$2.94M -161.0% |
| Operating Income | -$11.17M +35.4% |
-$17.30M +30.9% |
-$25.03M -22.8% |
-$20.38M -69.3% |
-$12.04M -13.8% |
-$10.58M |
| Gross Profit | $9.02M +9.0% |
$8.27M -17.4% |
$10.02M -20.5% |
$12.60M +21.0% |
$10.41M +20.3% |
$8.66M |
| Shares Outstanding | 5.89M +221.2% |
1.83M +99.2% |
920,592 -96.0% |
23.01M +26.4% |
18.21M +46.3% |
12.44M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $6.78M | +75.7% | +77.6% |
| Revenue (ASC 606) | September 30, 2025 | $6.78M | +75.7% | +77.6% |
| Net Income | September 30, 2025 | -$5.40M | -106.4% | -7.7% |
| Diluted EPS | September 30, 2025 | -$0.49 | -22.5% | +10.9% |
| Total Assets | September 30, 2025 | $25.64M | +67.1% | -1.5% |
| Cash and Equivalents | September 30, 2025 | $3.09M | -51.1% | -29.9% |
| Long-Term Debt | September 30, 2025 | $8.38M | — | +8.0% |
| Stockholders Equity | September 30, 2025 | $2.53M | -67.0% | -44.8% |
| Operating Income | September 30, 2025 | -$4.73M | -79.0% | +2.7% |
| Gross Profit | September 30, 2025 | $3.94M | +68.7% | +86.6% |
| Shares Outstanding | September 30, 2025 | 8.27M | +73.5% | +12.9% |
- Vivos Therapeutics, Inc. reported Total Revenue of $15.03 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +8.9% in Total Revenue compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Revenue (ASC 606) of $15.03 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +8.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Net Income of -$11.14 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +18.0% in Net Income compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Diluted EPS of $2.22 per share (loss) for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +80.1% in Diluted EPS compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Total Assets of $15.28 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +42.4% in Total Assets compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Cash and Equivalents of $6.26 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +281.0% in Cash and Equivalents compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Long-Term Debt of $423.0 thousand for fiscal year 2020.
- Vivos Therapeutics, Inc. reported Stockholders Equity of $7.95 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +1835.3% in Stockholders Equity compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Operating Income of -$11.17 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +35.4% in Operating Income compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Gross Profit of $9.02 million for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +9.0% in Gross Profit compared to the prior fiscal year.
- Vivos Therapeutics, Inc. reported Shares Outstanding of 5.89 million shares for fiscal year 2024.
- Vivos Therapeutics, Inc. showed an increase of +221.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: